Steven Freedman

Statistics

Publications

Citations

727

H-Index

Active since

1978

Affiliations

Biogen (United States)(Current)

Baylor University

Cleveland Clinic

Multiple Sclerosis Society

Heinrich Heine University Düsseldorf

Steven Freedman is an author at Biogen (United States) specializing in multiple sclerosis therapy, relapsing-remitting multiple sclerosis treatment, and life sciences.

Publications per year

1978–2019

Publications

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

David H. Miller, Robert J. Fox, J. Theodore Phillips et al. · Neurology · 2015 · 65 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

Double‐blind trial comparing flunisolide and placebo for the treatment of perennial rhinitis

J. Schulz, Jerry D. Johnson, Steven Freedman · Clinical & Experimental Allergy · 1978 · 36 citations

Life Sciences, Pharmacotherapy, Allergy +11

1–5 of 5